论文信息 - LONG-TERM OUTCOME OF ALTERNATING NILOTINIB 400 MG TWICE DAILY AND IMATINIB 400 MG ONCE DAILY AS FRONTLINE TREATMENT OF CHRONIC MYELOID LEUKEMIA: A PHASE 2 STUDY OF THE GIMEMA CML WORKING PARTY - 字舞流文

LONG-TERM OUTCOME OF ALTERNATING NILOTINIB 400 MG TWICE DAILY AND IMATINIB 400 MG ONCE DAILY AS FRONTLINE TREATMENT OF CHRONIC MYELOID LEUKEMIA: A PHASE 2 STUDY OF THE GIMEMA CML WORKING PARTY

M. Baccarani | G. Martinelli | G. Saglio | S. Soverini | F. Pane | M. Breccia | G. Alimena | G. Specchia | M. Cavo | A. Carella | L. Luciano | G. Rosti | M. Tiribelli | F. Stagno | F. Castagnetti | G. Gugliotta | B. Martino | E. Abruzzese | M. Bocchia | F. Cavazzini | A. Gozzini | G. Rossi | S. Luatti | E. Usala | C. Venturi | G. Rege‐Cambrin